At a glance
- Originator Roche
- Class Antihyperglycaemics; Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 26 Feb 2001 Profile reviewed but no significant changes made
- 30 Jun 1998 No-Development-Reported for Hyperlipidaemia in Germany (Unknown route)
- 30 Jun 1998 No-Development-Reported for Type-2 diabetes mellitus in Germany (Unknown route)